Timothy P Kelly has sold FIXX and made no open-market buys since Jun 2019

Timothy P. Kelly is a biopharmaceutical operations executive and corporate insider who has served as Chief Operating Officer (COO) of Homology Medicines, Inc. (NASDAQ: FIXX), a genetic medicines company focused on gene therapy and gene editing.( According to SEC-related insider trading databases, he is listed as “See Remarks” among key executives at Homology Medicines, alongside the company’s President & CEO Arthur Tzianabos and other senior scientific leadership, reflecting his senior officer status in the organization.( As a reporting insider, Kelly has made multiple Form 4 filings in Homology Medicines stock, including several sales of FIXX shares over the past five years.(

Kelly’s tenure at Homology Medicines included his promotion to Chief Operating Officer, a role in which he oversaw operational execution for the company’s genetic medicine programs.( SEC and market data services report that, as an insider, he has conducted at least eight FIXX stock transactions, all of them sales, with his most recent reported sale on January 5, 2022 noted in the filings as “See Remarks.”( These filings also show that he held a small residual share position following his transactions.( Beyond Homology Medicines, Kelly is identified in insider-trading and executive-tracking platforms as a C‑suite biopharma officer, including roles such as COO at other life sciences companies, underscoring his broader experience in operations leadership within the biotechnology sector.(

Written by Perplexity from public sources.